Publications by authors named "G Migneco"
Background: There has been limited success of cancer immunotherapies in the treatment of ovarian cancer (OvCa) to date, largely due to the immunosuppressive tumour microenvironment (TME). Tumour-associated macrophages (TAMs) are a major component of both the primary tumour and malignant ascites, promoting tumour growth, angiogenesis, metastasis, chemotherapy resistance and immunosuppression. Differential microRNA (miRNA) profiles have been implicated in the plasticity of TAMs.
View Article and Find Full Text PDFBACE1 is well-known for its role in the development of Alzheimer's disease. Recent publications, including our own, have demonstrated a role for this enzyme in other chronic diseases. The aim of this study was to investigate the role of BACE1 in the autoimmune disease systemic sclerosis (SSc).
View Article and Find Full Text PDFObjectives: We aimed to evaluate thrombotic and hemorrhagic complications with heparin versus bivalirudin use in veno-venous extracorporeal membrane oxygenation (V-V ECMO).
Methods: We performed a retrospective cohort study of adult patients placed on V-V ECMO with intravenous anticoagulation with either heparin or bivalirudin. Time to thrombotic event and major bleed were analyzed in addition to related outcomes.
Article Synopsis
- - Recent research highlights the need for innovative cancer treatments, particularly through the use of oncolytic viruses (OVs) that can attack tumors in multiple ways.
- - The study discovers a specific amiRNA, called amiR-4, that enhances the effectiveness of a type of oncolytic virus, revealing ARID1A as a key factor in tumor resistance.
- - Combining virus targeting of ARID1A with small-molecule inhibitors like EZH2 leads to effective killing of both infected and uninfected cancer cells, suggesting a new therapeutic strategy involving amiRNA and traditional treatments.
Background: It is well established that females and persons of racial and ethnic minorities are frequently underrepresented in clinical trials. These disparities are potentially important aspects of evidence-based formulary management and drug utilization review (DUR) processes.
Objective: The purpose of this study was to review the demographic composition of pivotal trials and post-approval study requirements for recent FDA-approved drugs, analyzing the representation of minority groups and its generalizability to the US population or corresponding disease state.